pharmaphorum April 18, 2023
A report from a UK think tank focused on the impact of longevity on society has found that people aged over 60 are still poorly represented in clinical trials – even though they are often the group new therapies are being developed to treat.
The study by the International Longevity Centre (ILC) urges regulators, pharma companies, and researchers to prioritise age diversity at all stages of the clinical trial process, pointing out that 60% of all prescriptions written in England between 2006 and 2016 were dispensed to some aged 60 or over.
At the same time, a 2014 study found that a third of all clinical trials excluded subjects based on their age, while another study in the US in...
Today's Sponsors
Today's Sponsor